Omega-3 PUFA-based therapy for Diabetes Mellitus: ω-PUFAs (DHA+EPA) augment the expression of FGF19 and FGF1,  attenuate hepatic glucose production, decrease hepatic acetyl CoA content, bring down the levels of plasma ACTH, and corticosterone, augment insulin sensitivity, promote weight loss and alleviate TIDM, via up regulation of its target gene, 7/April/2018, 11.12 pm